 | • レポートコード：MRC2203A834 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査資料では、世界のアテローム性動脈硬化症治療薬市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、薬剤分類別（抗血小板薬、コレステロール低下薬、フィブリン酸＆オメガ-3脂肪酸誘導体、ベータ遮断薬、その他）分析、流通チャネル別（小売薬局、病院薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来の傾向などの項目を掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のアテローム性動脈硬化症治療薬市場規模：薬剤分類別（抗血小板薬、コレステロール低下薬、フィブリン酸＆オメガ-3脂肪酸誘導体、ベータ遮断薬、その他） ・世界のアテローム性動脈硬化症治療薬市場規模：流通チャネル別（小売薬局、病院薬局、オンライン薬局） ・世界のアテローム性動脈硬化症治療薬市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Pfizer Inc.、AstraZeneca、Merck & Co., Inc.、...） ・市場機会・将来の傾向 |
The atherosclerosis drugs market studied was projected to grow with a CAGR of 2.2% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of atherosclerosis and cardiovascular diseases. According to the European Heart Network, 2017, every year, cardiovascular disease causes 3.9 million deaths in Europe and over 1.8 million deaths in the European Union. The maximum incidences of cardiovascular diseases can be attributed to the sedentary lifestyle in developed countries. The sedentary lifestyle leads to a high prevalence of high blood pressure, high cholesterol, obesity, and high alcohol consumption, which together contribute to a high incidence of cardiovascular diseases. Therefore, the sedentary lifestyle leading to a high prevalence of cardiovascular diseases and increasing awareness of the treatment options are expected to drive the market studied.
Key Market Trends
Cholesterol Lowering Medications Segment is Dominating the Atherosclerosis Drugs Market.
- Cholesterol-lowering drugs include statins and fibrates. The dominant share of the segment is attributed to the increasing prevalence of cardiovascular disease and high cholesterol, obesity globally. According to the World Health Organization in 2018, an estimated 40 million children under the age of 5 years were overweight or obese. A heightened intake of energy-dense foods that are high in fat and sugars, and an upsurge in physical immobility due to the increasingly inactive nature of many forms of work, changing modes of transportation, and increasing urbanization are factors propelling the high cholesterol rates and ultimately boosting the segment growth.
- Furthermore, the approval of novel cholesterol-reducing drugs is enhancing segment growth. For instance, the drugs, alirocumab (Praluent) and evolocumab (Repatha) belong to a new category of medications known as PCSK9 inhibitors which lower harmful LDL cholesterol values dramatically more than 50%. these types of novel treatment drugs boost segment growth. The increasing patient pool and increasing approvals of new drugs enhance the segment growth.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of cardiovascular diseases and atherosclerosis, established healthcare infrastructure are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. In this region the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. About 647,000 Americans die from heart disease each year, 1 in every 4 deaths. Heart disease costs the United States about USD 219 billion each year. As per the statistics, the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.
Competitive Landscape
The Atherosclerosis drugs market is moderately competitive and consists of several major players. Some of the companies which are currently dominating the market are Pfizer Inc., AstraZeneca, Merck & Co., Inc., Sanofi US, Amgen Inc., Novartis AG, GlaxoSmithKline Plc, Bayer AG, Mylan N.V., Eli Lilly and Company
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Prevalence of Atherosclerosis & Cardiovascular Diseases
4.2.2 Rising Awareness about Cardiovascular Diseases
4.3 Market Restraints
4.3.1 Low Diagnostic Rate
4.3.2 Availability of Generic Products
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug Class
5.1.1 Anti-platelet Medications
5.1.2 Cholesterol Lowering Medications
5.1.3 Fibric Acid and Omega-3 Fatty Acid Derivatives
5.1.4 Beta Blockers
5.1.5 Others
5.2 By Distribution Channel
5.2.1 Retail Pharmacies
5.2.2 Hospital Pharmacies
5.2.3 Online Pharmacies
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 AstraZeneca
6.1.3 Merck & Co., Inc.
6.1.4 Sanofi US and Regeneron Pharmaceuticals, Inc.
6.1.5 Amgen Inc.
6.1.6 Novartis AG
6.1.7 GlaxoSmithKline Plc
6.1.8 Bayer AG
6.1.9 Mylan N.V.
6.1.10 Eli Lilly and Company
7 MARKET OPPORTUNITIES AND FUTURE TRENDS